GAO: DEA, FDA lack procedures guiding drug scheduling decisions

At a time when addiction field professionals and advocates await a decision on the possible rescheduling of marijuana, a report from Congress's Government Accountability Office (GAO) has uncovered gaps in the overall evaluations conducted by the federal agencies involved in all drug scheduling decision‐making processes.